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Abstract 
While the model for conventional antimicrobial drug discovery is based securely on singular modes 
and sites of action, those associated with phenothiazinium photoantimicrobial candidates are both 
multifactorial and variable, resulting from oxidation events due to reactive oxygen species (ROS).  
The effective counteraction of such species and their variable targets is clearly problematic from the 
point of view of microbial resistance mechanism development, and offers considerable opportunity 
for the use of these agents in local infection control.  However, this also means that drug 
development cannot be carried out using similar methods to those employed for conventional 
agents.  Furthermore, these multifactorial photoantimicrobial agents are truly broad-spectrum since 
they are active against bacteria, fungi, viruses and protozoa, again at variance with the targeting of 
conventional, single-class antimicrobials. 
This review concentrates on the use of the phenothiazinium class as exemplar photoantimicrobials, 
due to their pre-eminence in the field and considers the various criteria required for successful 
activity against microbes.  These include alicyclic fusion, chalcogen substitution, benzo[a] fusion and 
the heavy atom effect, to decrease aggregation, improve ROS production and extend absorption 
wavelength, as well as conventional approaches, such as increasing cationic character to improve 
microbial selectivity/targeting. 
 
Keywords: drug resistance; methylene blue; phenothiazinium; photoantimicrobial; photosensitiser 
design. 
 
 
  
1. Introduction 
When Alexander Fleming made his fortuitous discovery concerning the observable 
antistaphylococcal behaviour of Penicillium mould exudate, his thought was, reportedly, that what 
was occurring was enzymic lysis of the bacterial target [1], and the penicillin class of antibacterial 
agents had been a clinical reality for a number of years before an accurate biochemical 
understanding of its action was revealed.  This class was therefore in widespread clinical use purely 
on the demonstrable bases of antibacterial efficacy and low human toxicity. 
The huge impact of the penicillins on infection control paved the way for the discovery of other 
major classes of antimicrobial drugs during the ‘golden age’.  However, in most cases, the cellular 
targets for modern therapeutics are the same as those discovered for the corresponding lead 
compounds, i.e. the drug target is determined from the original evidence of activity, rather than 
being chosen from a study of target cell biochemistry, morphology etc. – for example, the original 
chlortetracycline and the 21st Century glycylcyclines all act at the bacterial ribosome [2]; penicillin V 
and the carbapenems all act against bacterial peptidoglycan crosslinking [3].  Such an approach 
might be termed the ‘received target’ paradigm. 
In addition, few, if any, of the antibiotics discovered using this approach, or the semisynthetics 
derived from them, have more than a single site/mode of action, which is clinically problematic 
given the speed of microbial evolution, and is the reason that single-mode-of-action antimicrobials 
generally have limited useful lifetimes.  Indeed, Fleming himself alluded to the likelihood of penicillin 
resistance without drug conservation in his Nobel lecture [4]. 
In attempting to address the problem of rapid and increasing microbial drug resistance, the UK 
Government’s published Antimicrobial Research (AMR) Strategy, and the more recent O’Neill Report  
make several mentions of ‘novel approaches’ to the treatment and prevention of infections [5,6].  
One potential approach proposed – for several years now - as a partial replacement/conservation 
aid for conventional agents is that of light-activated or photoantimicrobials [7].  However, due to 
broad-spectrum activity, non-specific modes of action and the requirement for light activation, the 
design of such agents differs considerably from that of conventional, pharma industry-produced 
antimicrobials. 
 
2. Photoantimicrobial Chemotherapy (PACT [8]) 
The cell-killing effect of acridine and the synthetic xanthene dye eosin, in combination with light, 
was discovered by Raab in 1900 [9].  The organism under study was Paramecium caudatum, a single-
celled organism, and the phenomenon was shortly termed ‘Photodynamy’ (light causing action).  
Raab’s experimentation was of little utility in terms of drug design, given that the acridine and eosin 
used belong to quite different chemical classes (acridine and xanthene, respectively), absorb light in 
separate regions of the spectrum (ultraviolet/visible) and produce different oxidative cell-killing 
agents (Type I/Type II photosensitisation routes – see below).  However, the salient point was that 
this was the first reported laboratory demonstration of the photodynamic effect. 
During the first few decades of the 20th Century, much of the chemical industry was based around 
dye synthesis, and dyes were certainly tested widely in applications other than textile colouration.  
Pioneering work by Ehrlich, Koch and others had demonstrated the use of synthetic dyes for sample 
staining in microscopy and had allowed the quantum leap to the concept of selective toxicity before 
Raab’s photodynamic breakthrough.  Ehrlich, in particular, made great strides towards a dye-based 
chemotherapeutic approach, including early notions of structure-activity relationships before the 
First World War [10].  Indeed, ‘Flavine therapy’ of battlefield injuries - based on the direct 
application of cationic dyes (e.g. acriflavine and brilliant green) – evolved from work carried out by 
Browning with Ehrlich before the conflict [11]. 
Methylene blue is a cationic dye, based on the oxidised phenothiazine heterocycle (Figure 1), and 
used in Guttmann and Ehrlich’s clinical malarial cures in 1891 [12].  The lack of toxicity of this dye 
and the burgeoning interest in chemotherapy led to its use in a range of diseases [13].  However, its 
photoantimicrobial potential was not reported until – ironically - the same year as Fleming’s epoch-
making publication [14].  However, between 1928 and the clinical introduction of IG Farben’s 
Prontosil in the late 1930s, methylene blue had been shown to be bactericidal, virucidal and 
antiprotozoal on illumination [14,15]. 
 
 
Figure 1.  Methylene blue chloride 
 
Given the miracle drug status accorded the penicillins and ensuing antibiotics discovered/developed 
in the mid-20th Century, it is not surprising that there was scant further contemporary development 
of photoantimicrobials.  Such a renaissance resulted from the development of significant clinical 
microbial drug resistance during the 1980s.  Modern photoantimicrobial drug discovery has thus 
been in progress for around a quarter of a century [16], mainly in academia. 
 
3. Photoantimicrobial Action 
As noted, photoantimicrobials act via the absorption of light energy, producing reactive oxygen 
species as a result which represent a cytotoxic threat to simple microbial cells.  The confluence of 
photoantimicrobial, target cell, oxygen and light furnishes the basic conditions for cytotoxicity in 
practice, but consideration needs to be given to photoantimicrobial structure design to ensure 
efficient ROS production in vivo. 
Mechanistically, photoantimicrobial action occurs in the same way as that of the related clinical 
anticancer approach, photodynamic therapy (PDT).  On a molecular level, this involves the 
absorption of light of a specific wavelength (i.e. depending on the chromophore involved) to enable 
the promotion of a paired ground state electron to the singlet excited state (HOMO LUMO, spins 
still paired, Figure 2).  Given a long-lived singlet excited state, spin inversion yields the more reactive 
(unpaired) triplet excited state, and it is usually this which reacts with its environment, either 
through electron transfer with the molecular environment or energy transfer to ground state triplet 
oxygen (Type I or Type II photosensitisation pathways respectively).  The former results in the 
formation of the hydroxyl radical (HO.) and the superoxide anion (O2-), while the latter produces 
singlet oxygen (1O2) (Figure 2). 
 
 
 
Figure 2.  Photosensitisation pathways.  Key: S0 – singlet ground state; *S1 – singlet excited state; T1 – 
triplet excited state; h – light energy; IC – internal conversion; F – fluorescence; P – 
phosphorescence; ISC – intersystem crossing. 
 
Due to the oxidising and highly reactive nature of these species, they do not persist for extended 
periods - for example, 1O2 decays to its non-toxic ground state on a sub-microsecond scale.  
However, each will cause oxidation across a range of biomolecules involved in all parts of the cell, 
and close proximity of the photoantimicrobial to its target – whether internal or external – is thus 
normally sufficient to lead to cell death. 
 
4. Designing an effective photoantimicrobial 
For clinical use, a photoantimicrobial clearly requires a dual design strategy.  Unlike conventional 
agents, the photosensitisation requirement means that, alongside microbial selectivity, light 
absorption must be included as an essential component, and this must result in efficient conversion 
to ROS.  The key to photosensitisation lies in the production of a sufficient population of triplet 
excited state molecules (Figure 2).  This is supplied by a relatively long-lived singlet excited state, as 
exhibited by several lead structures such as the phenothiazinium derivative methylene blue [17].  
Furthermore, since excitation is dependent on light absorption, in the case of photoantimicrobials 
consideration must also be given to the circumvention of endogenous absorption, e.g. due to 
proteins, blood and melanin present at the infection site (Figure 3).  Red- or near infrared absorption 
is generally accepted as a means to this end, and this again requires further consideration in terms 
of overall drug design. 
 
 Figure 3.  Pertinent endogenous absorption spectra, the therapeutic window and current useful 
phenothiazinium absorption range. Hb – haemoglobin; OxyHb – oxyhaemoglobin. 
As noted above, the exquisite selectivity associated with conventional single-mode-of-action 
antimicrobials actually guarantees resistance development via selective evolutionary pressure.  With 
the multifactorial modes of action of photoantimicrobials, however, there is little requirement for 
targeting at the biomolecular level, and a much more general selectivity between host and target 
cells is preferable (see Microbial Selectivity, below). 
 
4.1 Microbial Selectivity 
Photoantimicrobials are truly broad-spectrum agents.  This offers advantages in the treatment of 
e.g. local bacterial infections due to mixed strains, or mixed Gram-positive / Gram-negative species, 
or of unknown aetiology.  Such a definition would be used for conventional antibacterial agents in 
the pharmaceutical sector.  However, for cationic photoantimicrobials this may be extended to the 
combined therapy of primary and secondary infections where the primary and secondary causes are 
of separate class – e.g. opportunistic bacterial colonisation of tissue damaged by initial fungal 
incursion, and similarly for infection due to emerging or unknown pathogens, whether these are of 
bacterial, fungal, viral or protozoal origin. 
For such activity the design model is, perhaps not surprisingly, similar to that of the original 
therapeutic dye work carried out by Ehrlich et al., i.e. uptake by microbial cell types - of whichever 
class - but not by the host.  Clearly there are various parameters which might be set in terms of 
molecular design to ensure such a distribution, such as molecular charge, hydrophilic-lipophilic 
balance or degree of molecular planarity.  While this is obviously far more straightforward an 
approach than those employed by modern pharmaceutical research, it remains an effective process 
for photodynamic drug design and discovery. 
 
Photosensitisers with net positive charge are established as the premier class of broad-spectrum 
agents, due to high activity against both Gram classifications.  This is not the case for electronically 
neutral analogues or those possessing overall negative charge, which tend to be considerably less 
effective against Gram-negative bacteria [18].  Given the significant problems engendered by Gram-
negative infections in modern healthcare, this is an important point.   Efficacy against fungi, viruses 
and protozoa cannot be simply differentiated in this way. 
The huge difference in complexity between mammalian and microbial cells explains the relatively 
simple and rapid binding, uptake and overall greater efficacy of cationic photoantimicrobials.  For 
example, methylene blue binds to anionic residues in the Gram-positive bacterial cell wall, such as 
teichoic acids [19], while at the outer membrane of a Gram-negative cell, it will displace calcium or 
magnesium ions which aid in stabilising the polar head groups of the outer membrane, thus allowing 
ingress of the photoantimicrobial, i.e. a self-promoted uptake mechanism [20]. 
It should be recalled, also, that the envisaged administration of photoantimicrobial agents and their 
subsequent illumination is via topical or otherwise local application – i.e. the site of infection is 
physically targeted at administration (whether externally or internally using endoscopy/fibre optics).  
The applied photosensitisers are thus far less exposed to distributional and metabolic factors than 
systemically-administered conventional drugs.  Similarly, there is far lower potential for damage to 
the host’s indigenous microflora. 
 
4.2 Chemical Considerations  
Given the low level of specification required in terms of structure, effective photoantimicrobials 
need only to consist – at base level - of a chromophore or chromophore-auxochrome combination 
which allows long-wavelength light absorption and efficient ROS production, and net molecular 
positive charge.  The phenothiazinium class of cationic or basic dyes provided the initial lead 
compounds here, e.g. methylene blue and the related toluidine blue (Figure 4). To these have been 
added de novo cationic derivative series of the phthalocyanine, porphyrin and cyanine classes – all 
containing strong red light absorbers.  However, there is far greater evidence and rationale for the 
original class, given not only its use in microbial staining for the past 150 years, but also its 
continuing clinical – local and systemic - applications in intraoperative staining and the treatment of 
methaemoglobinaemia [21]. 
 
 Figure 4.  Lead phenothiazinium photoantimicrobials, identifying auxochromic (methylene blue) and 
chromophoric (toluidine blue) moieties, and the importance of the auxochrome in promoting long-
wavelength absorption (max values measured in methanol). 
 
4.3 Phenothiazinium Derivatives - Photoproperties 
Both methylene blue (max = 660 nm in aqueous solution) and toluidine blue (625 nm) exhibit intense 
light absorption in the red region of the spectrum.  In terms of the avoidance of interference from 
endogenous absorbers, this is sufficient, given that haem absorption reaches a minimum at around 
630 nm (Figure 3).  However, considerable efforts have been made in extending phenothiazinium 
absorption further into the red region (bathochromic shifting) due to the clinical desirability of 
increased tissue penetration of light, which reaches a maximum between 800-900 nm [22]. 
 
4.3.1 Aggregation 
Photosensitisation relies on initial efficient interaction of incident light with the sensitiser molecule.  
Interference with this process is therefore undesirable.  As noted above, in practice such 
interference occurs when incident light is absorbed by molecules in the environment of the 
photosensitiser, i.e. endogenous absorption, but photosensitiser aggregation may also problematic. 
Aggregation is a common phenomenon associated with planar molecules, and is thus a well-
understood feature in dye chemistry.  Clearly, the greater the degree of molecular planarity, the 
easier it is for stacking interactions to occur, and these will usually increase with concentration.  
Molecules within the body of the aggregate are not reached by incident light, thus 
photosensitisation is only possible at the surface.  Similarly, energy transfer to oxygen is less likely 
within the tight confines of the aggregate. Furthermore, most aggregated photoantimicrobials 
exhibit an absorption band at lower wavelengths than the max. This may bring the absorption into 
competition with endogenous species, as mentioned previously. 
It is thus important to design photosensitiser molecules which exhibit low aggregational behaviour.  
This is normally achieved via the inclusion of chemical groups which are either bulky and/or charged, 
thus causing intermolecular repulsion.  In addition, monomeric species, as opposed to oligomeric or 
aggregated species, could be expected to be taken up or to bind to biomolecules more effectively 
due to smaller molecular volume. 
 
4.3.2 Auxochromic Derivatives 
 
Clearly auxochromic alteration+ can affect various properties of colourant molecules, given that 
there are both associated steric and electronic factors.  Thus, for example, in the present case, 
altering the auxochromic character might cause wavelength shifting as well as altered ROS 
production, aggregation and hydrophilic/lipophilic balance. 
As noted above, interference by endogenous molecules in light absorption processes can be 
detrimental to photoantimicrobial performance, requiring design to produce molecules which 
absorb beyond endogenous range. 
Using the 3,7-diaminophenothiazinium (thionin) skeleton as a basic framework, it can be seen that 
consecutive amino substitution with methyl groups causes regular bathochromic shifting of the max 
up to methylene blue. 
  
  
Figure 5. HOMO/LUMO and orbital energy dependence on extent of N-methyl substitution.  Key: T – thionin; 
AzC – azure C; AzA – azure A; AzB – azure B; MB – methylene blue. 
 
Figure 5 shows the highest-occupied molecular orbitals (HOMO, lower) and lowest unoccupied 
molecular orbitals (LUMO, upper) of thionine, azure A and methylene blue from left to right 
respectively. The small graph on the right shows these orbital energies as a function of the number 
of N-methyl substituents and the main graph the difference in energy between LUMO and HOMO 
(EL-EH), again as a function of the extent of N-methyl substitution. 
Overall it can be seen that orbital density is weakly transferred from ‘out’ to ‘in’ comparing HOMO 
and associated LUMO, with significant enhancement of orbital density on the N and S atoms in the 
LUMO and associated decreases in orbital density associated with N-methyl groups in the HOMO. 
N-Methyl substitution leads to a systematic increase in both HOMO and LUMO orbital energies. This 
can be rationalised by the increasing number of nodes appearing in the both orbital sets as N-methyl 
substitution is increased from left to right above. Furthermore, there is greater orbital density on the 
N-methyls in the HOMOs than LUMOs leading to a greater sensitivity of the HOMOs than LUMOs 
energy to such substitution. In other words, the anti-bonding character of the HOMOs is more 
sensitive to N-methyl substitution than in the LUMOs and therefore the energy dependence is 
greater in the former than the latter. 
In short, assuming that the lowest energy electronic transition is 100% HOMO->LUMO in character, 
then the HOMO-LUMO energy gap reduces upon increasing the extent of N-methyl substituent 
E / kJ mol
-1
 
LUMO 
HOMO 
primarily due to the systematic raising in energy of the HOMO to a greater extent than that of the 
LUMO due to variation in the significance of hyperconjugation effects in the two orbitals. 
Vertical excitation energy is a function of the HOMO/LUMO energy gap and changes in electrostatic, 
Q, and exchange interaction, K, energies resulting from the single electronic occupancy of both 
orbitals in the vertical E/S geometry; EabsV = + Q + K.  and K are always positive energy 
contributors to vertical  S1 energy, Q may be positive or negative. Assuming that Q and K are the 
same for all structures in the group, there ought to be a correlation between EL-EH) and max / 
Eobsmax observed in the absorption spectrum. A graph of ELH versus Eobsmax for all commercially-
available MB derivatives is given below (Figure 6). 
 
 
Figure 6. Plot of ELH versus Eobsmax. dark blue = N-Me substituents, green = MG, orange = NMB =, yellow = 
DMMB and red = TBO. The darker blue from left to right correspond to 4, 3, 2, 1, 0 N-methyl groups 
respectively. 
While Figure 6 clearly shows a sound correlation in terms of max, this approach is of less utility in 
predicting the ability of putative molecules to produce singlet oxygen. 
 
Auxochromic variant synthesis 
The use of iodine or bromine oxidation in phenothiazinium synthesis has allowed considerable range 
extension compared to earlier work, for example by Taylor, which was perforce limited both by 
reactant aqueous solubility and stability to the strong oxidising agents employed (usually 
chromium(VI)) [24].  Iodine oxidation of 10H-phenothiazine produces the oxidised phenothiazinium 
chromophore which is reactive to nucleophiles at both positions 3- and 7-, and can be attacked 
sequentially.  This allows the synthesis of both symmetrically and asymmetrically-substituted 
derivatives [23].  Similarly, bromine oxidation furnishes 3,7-dibromophenothiazinium bromide, in 
which the bromines can be replaced by amines, although this route is more suitable for the 
production of symmetrical derivatives.  Both approaches are carried out in organic solvents and thus 
allow the inclusion of long-chain auxochromes.  General synthetic routes to phenothiazinium 
derivatives are shown in Figure 7. 
Principally in this class of photoantimicrobials, absorption of light at increased wavelength (i.e. 
usually further into the red region) has been achieved by greater electron release from the 
auxochromic amino groups at positions 3- and 7-of the phenothiazinium chromophore, normally by 
increasing the alkyl group size.  This is shown for the series of simple methylene blue homologues 
first fully published by Mellish et al. [25] (Table 1, synthesised via route (a), Figure 7).  Importantly, 
such substitution also retains the capacity for efficacious ROS production.  Extension of this idea to 
auxochromic N-aryl or N-heteroaryl substitution also allows significant bathochromic shifting [26], 
but in this case decreases ROS production to minimal levels, and so is of little utility in development.  
Aromatic inclusion without a concomitant loss of ROS production capability has been achieved using 
benzylamine derivatives to provide the auxochromic moiety (Route (a), Figure 7).  This also allows 
the potential for photosensitiser functionalisation – e.g. for polymer attachment - without 
deleterious effects on chromophore performance [26]. 
 
 
Figure 7.  Basic synthetic routes to phenothiazinium derivatives.  Key: (i) iodine; (ii) HNR 2 (providing 
symmetrical derivatives), or HNR2, followed by HNR’2 (providing asymmetrical derivatives); (iii) 
bromine; (iv) HNR2; (v) mild oxidant, e.g. silver(I) carbonate.  Auxochromic substituent groups are 
usually alkyl, aryl, aralkyl or substituted derivatives thereof; R”’ and X may be H.  Chromophoric 
substituents R” / R* are usually electron-releasing.  This approach is also used to produce 
benzannelated / dihydropyrrolo- / tetrahydropyrido-derivatives (tetra- and pentacyclic molecules, 
see below). 
  
 
R max 
(nm)a 
Log maxa Rel.
1O2a LogP 
Me 657 4.88 1.00 -0.1 
Et 664 4.87 0.55 +0.8 
n-Pr 669 4.75 0.59 +1.1 
n-Bu 671 4.84 0.61 +1.3 
n-Pe 672 4.69 0.26 +1.6 
n-Hx 673 4.55 0.21 +1.8 
 
Table 1.  Simple homologous series of photosensitisers based on methylene blue. a – measured in 
methanol [25]. 
 
Auxochrome decay 
Conversely, N-demethylation of methylene blue is a straightforward oxidative process, as with other 
N-methylated dye or drug molecules.  This has been understood almost from the initial experiments 
with the parent compound in the 19th Century, since it was, at the outset, undoubtedly a mixture of 
methylated derivatives due to the oxidative nature of its preparation.  As shown in Figure 8, 
successive demethylation of the parent produces five further derivatives, all of which are 
photosensitisers.  However, the loss of auxochromic methyl groups also causes a drop in absorption 
wavelength, due to decreased electron release from the demethylated auxochrome. This, as noted 
above, brings into play competition for excitational energy with endogenous absorbers such as haem 
and melanin. 
 
  
Figure 8.  Demethylation in the methylene blue series and maximum aqueous wavelength of 
absorption (nm). 
From a design viewpoint, facile demethylation is problematic.  One of the principal legislational 
barriers in photoantimicrobial development is compound purity.  Consequently, an agent which 
decays into a mixture will be required to show efficacy/toxicity profiling of each of the daughter 
products.  As a result, despite the clinical acceptance of methylene blue for conventional human use, 
it is may not always escape this requirement as a photoantimicrobial agent. 
While such dealkylation is less likely in higher homologues, these are, by definition, new compounds 
without prior clinical use and are therefore subject to full drug legislative requirements.  
Auxochrome functionalisation is also useful in altering solubility – i.e. via the increase in hydrophilic 
or hydrophobic character.  This is particularly simple with the advent of the halogen oxidation routes 
(Figure 7 (a)/(b)), since this also allows asymmetric substitution with respect to the incoming amines, 
for example 3-(long chain dialkylamino)-7-diethanolamino or similar. 
This approach has been extended to include extra amino functionality as a part of the auxochromic 
side chain, both by the current author [27], Maisch [28] and Boyle [29], usually employing route (a) 
shown in Figure 7.  Given that this produces derivatives with extra cationic sites in the side chain, it is 
attractive from the point of view of designing molecules for antimicrobial attack, for example at the 
outer membrane of Gram-negative bacteria.  Ironically, such a pattern of functionality is apparent in 
(conventionally) antimalarial methylene blue derivatives produced under the IG Farben umbrella in 
the 1930s [30], although such examples were limited by the strong oxidant/aqueous media 
conditions noted above (route (c), Figure 7).  Side-chain amino functionality has also allowed the 
extension to dimeric examples, i.e. where the distal amino group provides a site for nucleophilic 
attack on the oxidised monoauxochromic precursor (Figure 7).  Hypothetically at least, this type of 
photosensitiser would be able to act as a ‘hairpin’  in attacking – typically - viral DNA in blood product 
photodisinfection protocols [31]. 
  
4.3.3 Chromophoric Alteration 
The central functionalisation of phenothiazinium photosensitiser structures is complicated by the 
requirement for amino moieties at positions 3- and 7-.  In addition, direct functionalisation often 
damages in situ substitution patterns, leading to a loss of activity.  However, chromophore 
methylation of both lead compounds, methylene blue and toluidine blue, has been reported, such 
syntheses utilising methylated starting materials, via route (c), Figure 7 [32-34]. 
The position of the methyl (or other alkyl group) in the precursory aniline is important, since rotation 
of the amino moiety to coplanarity with the aromatic nucleus is required in order to facilitate the 
oxidation reaction which furnishes the required phenothiazinium chromophore (Figure 7).  Clearly, 
close group proximity causes inhibition of this rotation and blocks the reaction. Thus, in the case of 
methylene blue, chromophore methylation is only possible at positions 1- and 9- (Figure 9), due to 
steric interference by the dimethylamino auxochromes [32].  1,9-Dimethylmethylene blue (DMMB, 
Taylors’s Blue, Figure 9) is a powerful photosensitiser against both microbial and mammalian cells, 
thus its utility in clinical terms may be limited by host toxicity problems.   The similarly powerful new 
methylene blue (NMB, Figure 9) also suffers from toxicity problems, but is structurally interesting as 
it exhibits 2,8-dimethylation, allowed due to monoethylated amino auxochromes (Figure 9 – 
auxochrome rotation also allows potential 4,6-dialkylation). Clearly, on a structural basis, NMB is 
mis-named. 
  
  
Figure 9.  The phenothiazinium nucleus, steric auxochromic hindrance and alkylation pattern.  
Arrows denote potential alkylation sites for the given auxochromic dispositions in methylene blue (a) 
and the 3,7-di(ethylamino) congener, (b). 
Functionalisation of the toluidine blue nucleus is somewhat more straightforward due to the 
absence of any auxochromic alkylation at C-3, and several mono-, di- and trimethylated derivatives 
have been produced [34].  However, as with DMMB above, one effect of methylation is a decrease in 
max from the parent which, in the case of toluidine blue, means that the resulting derivatives would 
be in greater competition with endogenous absorbers in the clinical situation. 
  
  
PS R R1 R2 R9 max (nm) 
MB Me H H H 656 
1-MMB Me Me H H 655 
DMMB Me Me H Me 650 
Azure A H H H H 633 
TB H H Me H 626 
1-MTB H Me Me H 616 
9-MTB H H Me Me 615 
Table 2.  Depression of max with chromophore methylation (measured in methanol) 
 
Given that, as a photoantimicrobial, toluidine blue already represents successful chromophore 
methylation – it could alternatively be named 2-methylazure A (see Table 2) – varying chromophoric 
substitution at position 2 has also been investigated (Figure 10 [35]).  In order to maintain 
photoactivity, hydrocarbon replacements were made, including simple alkyl and aryl.  All 
replacements led to increased photoantimicrobial activity compared to the parent compound and 
increased max to such an extent that the series approaches the methylene blue derivatives. 
 
 
  
Figure 10.  Photobactericidal activity of simple toluidine blue derivatives compared to conventional 
levofloxacin (Levo).  MBC = minimum bactericidal concentration.  Key to bacterial species: S. aureus 
– Staphylococcus aureus (Gram +ve bacterium); E. coli – Escherichia coli (Gram –ve); P. mirab – 
Proteus mirabilis (Gram –ve); Ps. aer – Pseudomonas aeruginosa (Gram –ve) [35]. 
 
The increased photoantimicrobial activity in the series, relative to the parent compound, may be 
linked to the decreased aggregation exhibited by the derivatives, as can be seen in Figure 11 for the 
tert-butyl analogue.  Its activity against the problematic Gram-negative pathogen Pseudomonas 
aeruginosa (MBC =390 nM) is extremely impressive, particularly when viewed against that of the 
conventional fluoroquinolone antibacterial drug levofloxacin. 
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 Figure 11.  Aqueous visible spectra for toluidine blue (pale grey curve) and its 2-t-butyl analogue 
(black), showing the more pronounced aggregate peak at lower wavelength for the parent 
compound. 
 
4.3.4 Annelation 
Chromophoric ring fusion has also been exemplified in the phenothiazinium series as a source of 
novel photosensitisers, utilising both aromatic and alicyclic annelative routes, in both cases leading 
to further red-shifting.  This is shown for simple derivatives in Figure 12. 
 
 
 
Figure 12.  Wavelength shifting in annelated derivatives.  Wavelengths measured in methanol: (a) 
Azure A; (b), (c) [36], (d) [37]. 
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 The benzo[a]phenoxazinium derivative Nile blue has been an established histopathological stain for 
around a century.  Due to demonstrable tumour staining in vivo, it was used by Foley as an 
alternative lead to the ubiquitous haematoporphyrin derivative in anticancer photosensitiser 
discovery in the late 1980s.  However, as the ring oxygen-inclusive chromophore produces no 
measurable singlet oxygen, lower period chalcogens were tested, and both sulphur and selenium 
incorporation proved fruitful.  Similarly, ring bromination or iodination of the 
benzo[a]phenoxazinium provided photosensitisers (Table 3).  The derivative EtNBSe (Table 3) has 
shown considerable potential as a photoantimicrobial agent [38]. 
 
 
 Z X R max 
(nm)a 
Relative 
1O2 yielda 
Methylene blue - - - 656 1.00 
NBA [39] H O H 623 0.01 
NBDI [40] I O H 642 0.08 
NBS [39] H S H 645 0.06 
EtNBSe [41] H Se Et 661 1.77 
 
Table 3.  Benzo-fused azine photosensitisers (NBD) and comparison with methylene blue.  a- 
measured in methanol. 
 
The employment of lower period elements in dyes is an established method of stabilisation of the 
singlet electronic excited state (Figure 2) which, as previously stated, normally increases the 
probability of triplet state population (via intersystem crossing) and reaction / energy transfer.  This 
is generally known as the Heavy Atom Effect.  Interestingly, however, neither the homologous series 
of seleno-methylene blue derivatives [42] nor iodomethylene blue [37] showed significant increases, 
either in max or in singlet oxygen yield. 
However, in terms of molecular design, the presence of heavy atoms will also alter the 
hydrophilic/lipophilic balance and thus the distribution and uptake of the resulting compounds at 
the biological target, as can be seen with respect to compound lipophilicity (as Log P) in Table 4. 
  
 X Y max (nm) 
1O2 eff. LogP 
NBA O H 623 0.005 +2.23 
NBA-6I O I 642 0.036 +3.75 
NBS S H 645 0.024 +2.55 
NBS-6I S I 660 0.170 +3.70 
 
Table 4.  Heavy atom inclusion for improved photoproperties and variation in Log P for 
benzo[a]phenothiazinium derivatives [40,43] 
 
Regarding photoantimicrobial activity, as with the anticancer application, the 
benzo[a]phenoxazinium derivatives are photodynamically inactive due to poor conversion to the 
triplet excited state.  Consequently, for the short 5-ethylamino series, broad-spectrum efficacy 
followed the expected trend, with the ring-selenium analogue (EtNBSe, Table 3) being the most 
active and having the greatest triplet yield [44]. 
 
The high activity of EtNBSe has also been demonstrated against Leishmania major [45], again 
demonstrating improved uptake and activity compared to both the sulphur analogue and the anionic 
porphyrins utilised for comparison.  Such work is also notable in that it demonstrates a fitting 
avenue for the employment of the photoantimicrobial approach, viz. tropical skin disease, offering 
rapid and relatively inexpensive therapy in less affluent areas.  Also fitting, of course, is the fact that 
Ehrlich’s own efforts in early chemotherapy utilised dye-based molecules against the scourge of 
tropical disease [46]. 
In terms of specifically targeting microbial cells via structural alteration, little has been essayed.  
However, work testing the “charge hypothesis” – i.e. the greater efficacy of cationic species as 
broad-spectrum agents - was carried out on a short series of Nile Blue (EtNBS) analogues by Vecchio 
et al.  Unsurprisingly, the incorporation of a guanidine residue as part of an auxochromic side chain 
(EtNBS-G, Figure 13) produced the most active compound of the series, the permanent extra 
positive charge so endowed producing high activity against both Gram-positive and Gram-negative 
bacteria [47]. 
  
  
Figure 13.  Photoantimicrobial Nile Blue derivatives 
 
4.3.4.1 Auxochrome rigidification - tetrahydropyrido[3,2-b]- and dihydropyrrolo[3,2-
b]phenothiazinium derivatives 
Fused alicyclic ring derivatives may be thought of as a variation on annelation as covered above.  
However such examples are synthesised from reduced indoles or quinolines and combine the 
advantages of both ring fusion and alkyl group size increase.  In addition, as the auxochromic 
nitrogen is part of the ring system, the auxochrome is therefore rigidified.  Due to this, such 
(pentacyclic) derivatives represent the longest wavelength-absorbing conventional (i.e. amino 
auxochrome) phenothiazinium derivatives reported thus far, max values approaching 700 nm (Figure 
14) [48].  The simplest derivatives for five- and six-membered fusion are shown in Figure 14, the six-
membered (tetrahydropyrido-) system being slightly bathochromically shifted relative to the smaller 
ring fusion. 
 
Figure 14.  Variation in max (measured in water) between five- and six-membered ring-fused 
phenothiazinium derivatives (azure B included in parentheses for comparison).  
As expected, the higher hydrocarbon content furnished by double ring fusion produced derivatives 
of higher lipophilicity/lower aggregation and this was further increased by alkyl ring substitution.  In 
terms of photoantimicrobial efficacy, derivatives such as S137 and its congeners (Figure 14) are 
highly active, moreso, indeed than the powerful, established familial photosensitisers dimethyl 
methylene blue and new methylene blue, achieved via strong interaction with/disruption of 
membrane structures [49].  An example of such high activity may be seen in Figure 15, where this is 
demonstrated against Propionibacterium acnes, and relative to the ‘industry standard’, benzoyl 
peroxide [50].  The properly photoantimicrobial nature of high-performing derivatives, such as S137, 
has been evidenced via similar efficacy against pathogenic species of Candida and Trichophyton spp. 
[51, 52].  Clearly, in both instances, such activities are encouraging, given the ease of application of 
photosensitiser and light to skin and nails. 
 
 
Figure 15.  Photoantimicrobial activities of tetra- and pentacyclic derivatives vs. Propionibacterium 
acnes.  BPO – benzoyl peroxide; MB – methylene blue; TBO – toluidine blue; DMMB – dimethyl 
methylene blue; S137 structure as Figure 14; pale grey columns – light activation; black columns – no 
illumination. 
 
4.4. Photoantimicrobial Progress 
Testing or screening potential drug candidates is an essential step in the design/development 
process.  Clearly the function of photoantimicrobials is to kill or otherwise inactivate the microbial 
target and this is performed via the intermediacy of reactive oxygen species.  While it is simple to 
measure the production of ROS spectrophotometrically, from a design viewpoint this is often a 
redundant step given that differences in solvent, oxygenation and – importantly – biomolecular 
binding and aggregation affect light absorption and any subsequent photosensitisation process.  It is 
therefore much more efficient, in terms of molecular ranking, to carry out photosensitisation testing 
against a realistic microbiological target.  A candidate photosensitiser may produce singlet oxygen 
with great efficiency in spectrophotometric testing, but exhibit little interaction with, or uptake by, 
the microbial target, thus being unable to focus its photosensitising potential effectively.  
Consequently, the process of photoantimicrobial ranking is somewhat streamlined by testing directly 
with the pertinent target. 
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Perhaps surprisingly, despite its long use in medicine and consequent presence as the obvious lead 
compound in this research area, methylene blue is far from being the perfect photoantimicrobial 
agent.  As noted previously, there are various criteria to take into account in designing active agents, 
one of which is the hydrophilic/hydrophobic balance.  MB (Log P = -0.1) is very hydrophilic, and this 
can inhibit its passage into cells.  Conversely, the lack of uptake (or slow uptake, relative to the 
microbial target) by mammalian cells is obviously an advantage from a host toxicity viewpoint.  It is 
also highly aggregated, due to its simple, planar structure and this may, again, inhibit the 
photodynamic process, as discussed above. 
This is not to say that MB is a bad photoantimicrobial agent.  However, it is the lead compound in 
the field mainly due to its long use and safety, rather than a sparkling reputation for photodynamic 
performance.  Many novel candidates have been synthesised which have been reported to be far 
superior in initial and further screening against relevant biological targets [49], and there is now a 
sound understanding of the structure-function relationships for this class of photosensitisers (Figure 
16).  The fact remains, however, that regulatory bodies are more concerned with safety than with 
high performance. 
 
 
Figure 16. Overview of structure-function in phenothiazinium-based photoantimicrobials 
 
Consequently, there are other hurdles to overcome before clinical acceptance is achieved, 
principally involved with drug safety.  While academic groups and small, spin-out companies are able 
to carry out a considerable amount of pre-clinical testing, there is usually a huge funding gap 
between this and patient trialling [16].  Given that supplying this gap appears most unappealing 
either to the pharmaceutical industry or healthcare concerns, it is surprising that there is a similar 
lack of appetite from venture capitalists.  The risk is high, certainly, but the marketplace for effective 
new anti-infectives has not been so ripe for exploitation since before the original sulphonamide 
breakthrough in the 1930s [53]. 
Furthermore, the local application of both the photoantimicrobial and light automatically suggests 
skin infections as the primary targets.  In turn this leads not only to the ‘conventional’ skin and soft 
tissue infections such as burns, ulcers and surgical wounds seen in healthcare in the industrialised 
nations, but also tropical infections such as leishmaniasis, trypanosomiasis and Buruli ulcer.  Clearly 
there are other localised infected presentations inside the body which might still be reached using 
fibre optics. 
Blood product photodecontamination has been in use for over 20 years [54], plasma being treated 
with methylene blue to remove infective agents in several regions (including Europe).  However, 
toxicity concerns – both in terms of cellular component damage and potential host toxicity - have 
inhibited the development and introduction of improved photoantimicrobial agents to such an 
extent that research in this area might now be considered a backwater.  Once again, this is surprising 
when the size of the blood products industry worldwide is taken into account.  
 
5. Conclusion 
The renaissance of research into photosensitising compounds suitable for infection control has been 
in existence for approximately a quarter of a century.  The impetus for this was, and remains, the 
ceaseless global increase in conventional antimicrobial resistance, and the phenothiazinium class of 
photosensitisers remains the principal model, with the lead compound methylene blue being the 
‘first in class’ clinical entry. 
Structure-function and, to a lesser extent, structure-activity relationships have been developed for 
this class of agents and the design and synthesis of novel congeners is relatively straightforward, 
with the main difficulty now being the movement of long wavelength absorption into the near-
infrared region to assist in tissue penetration for deeper infected presentations. 
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